NCT02977364Unknown1 期
Phase I Trial to Investigate Safety and Tolerability Profile and Pharmacokinetics of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours
Jiangsu Hansoh Pharmaceutical Co., Ltd.1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2016年11月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- MTD of HS-10241 based on the incidence of dose limiting toxicities
研究概览
简要总结
To investigate safety, tolerability and pharmacokinetics of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours that are not eligible for conventional or intensive treatment. The dose of HS-10241 will be escalated to determine the dose limiting toxicity (DLT) and the maximum tolerated dose (MTD) of HS-10241 in advanced cancer patients. At the same time, pharmacokinetic characteristics and preliminary efficacy of HS-10241 will be observed in advanced cancer patients. To determine the recommended dosage regimen for phase II.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed advanced or metastatic solid tumor for which standard therapy does not exist, has failed, or has been refused.
- •c-MET positive patients preferred in dose escalation phase; c-MET of patients must fulfill ICH++~+++ or FISH≥4 times in dose expansion phase.
- •Confirmed that there are at least 1 can be measured in accordance with the standard RECIST1.1 by CT or MRI.
- •18 ~65 years of age.
- •ECOG performance status of 0~
- •Life expectancy of at least 3 months.
- •Recovered from toxicities of prior anti-cancer treatment to Grade 1 or less (except alopecia).
- •Acceptable hematologic status (without hematologic supports including hematopoietic factor, blood transfusion) defined below:
- •Absolute neutrophil count (ANC) ≥ 1500/μL
- •Platelet count ≥ 100000/μL
- •Hemoglobin ≥ 9.0 g/dL
- •Acceptable liver function defined below:
- •Total bilirubin ≤ 2 times upper limit of normal range (ULN)
- •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 times ULN; however, ≤ 5 times ULN in a subject who has liver metastases
- •Acceptable renal function defined below:
- •Serum creatinine ≤ 1.5 times ULN or calculated creatinine clearance (by the Cockcroft-Gault formula) ≥ 60 mL/minutes
- •Acceptable coagulation status defined below:
- •Prothrombin time < 1.5 times ULN
- •Partial thrombin time < 1.5 times UL
- •HIV Ag/Ab(-).
- •HCV Ab(-);or HCV Ab(+) but HCV RNA(-).
- •HBsAg（-）and HBcAb（-）in dose escalation phase；HBV DNA<1×103copies/ml if HBsAg（+）or HBcAb（+）in dose expansion phase.
- •Ability to understand the purposes and risks of the trial and his/her informed consent using the human research ethics committee (HREC) approved informed consent form was obtained before the entering the trial.
排除标准
- •Treatment with other c-MET TKI( specific target or multi-target)；
- •Anti-cancer treatment with radiation therapy（not including non target lesions receiving palliative radiotherapy）, chemotherapy,hormonotherapy or surgery（small surgery, including the implantation of external equipment or fine needle aspiration, at least 7 days; diagnostic or palliative surgery, at least 14 days） within 4 weeks (6 weeks for nitrosoureas or Mitomycin C)prior to trial entry.
- •Medical history of difficulty swallowing, malabsorption or other chronic gastrointestinal disease, or conditions that may hamper compliance and/or absorption of the tested product
- •Cardiac disease with New York Heart Association (NYHA) Class III or IV, including congestive heart failure, myocardial infarction within 6 months prior to the trial entry, unstable arrhythmia, or symptomatic peripheral arterial vascular disease.
- •Symptomatic brain metastases or unstable brain metastases (notes: Patients with asymptomatic brain metastases previously treated for the study, but must be kept stable for at least 4 weeks and receive a stable dose of the drug)
- •Obvious neurological and mental disorder.
- •Other previous or concomitant tumors (except for the effective treatment of melanoma, cervical carcinoma in situ, ductal carcinoma in situ or malignant tumor after effective treatment, remission 3 years and considered to have been cured).
- •Active, uncontrolled bacterial, fungal infections, requiring systemic therapy.
- •Recent venous thrombosis (including deep vein thrombosis or pulmonary embolism within 0.5 year of trial entry)
- •History of organ allograft, autologous stem cell transplantation, or allogeneic stem cell transplantation.
- •Participation in an investigational drug or device trial within 4 weeks prior to the trial entry.
- •Anti-cancer treatment with radiation therapy, chemotherapy or immunotherapy within 4 weeks (6 weeks for nitrosoureas or Mitomycin C) prior to trial entry.
- •Major surgery, other than diagnostic surgery, within 4 weeks prior to the trial entry, without complete recovery
- •Taking a medication that is a moderate or strong inhibitor or inducer of CYP2C9; taking a medication that prolongs QT interval and has a risk of Torsades de Pointes .
- •Pregnant (positive serum beta human chorionic gonadotropin [β-HCG] test at Screening) or is currently breast-feeding, their partner anticipates becoming pregnant/impregnating during the trial or within 6 months after receiving the last dose of trial treatment.
- •Known drug abuse or alcohol abuse.
- •Concomitant disease or condition that could interfere with the conduct of the trial, or that would, in the opinion of the Investigator, pose an unacceptable risk to the subject in this trial.
研究组 & 干预措施
HS-10241 100mg
Experimental
HS-10241 100mg daily
干预措施: HS-10241 (Drug)
HS-10241 200mg
Experimental
HS-10241 200mg daily
干预措施: HS-10241 (Drug)
HS-10241 400mg
Experimental
HS-10241 400mg daily
干预措施: HS-10241 (Drug)
HS-10241 600mg
Experimental
HS-10241 600mg daily
干预措施: HS-10241 (Drug)
HS-10241 800mg
Experimental
HS-10241 800mg daily
干预措施: HS-10241 (Drug)
HS-10241 1000mg
Experimental
HS-10241 1000mg daily
干预措施: HS-10241 (Drug)
结局指标
主要结局
MTD of HS-10241 based on the incidence of dose limiting toxicities
时间窗: 4 weeks
次要结局
- Progression-free survival (PFS)(12 months)
- Max concentration (Cmax) of HS-10241(4 weeks)
- Objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumours (RECIST) v1.1(8 weeks)
- Incidence and intensity of Adverse Events according to Common Toxicity Criteria for AEs (CTCAE version 4.0)(8 weeks)
- Area under the plasma concentration versus time curve (AUC) of HS-10241(4 weeks)
- Elimination half-life(T1/2) of HS-10241(4 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
PhaseⅠStudy of the HS-10241 in Patients With Advanced Solid TumorsSolid TumorNCT04477057Jiangsu Hansoh Pharmaceutical Co., Ltd.30
Unknown
1 期
Tolerability, Safety, Pharmacokinetics and Efficacy of HS-10241 Single Agent or Combined With Apatinib in Patients With Advanced Solid TumorsAdvanced CancerNCT03243643Jiangsu Hansoh Pharmaceutical Co., Ltd.80
终止
1 期
Study of Safety and Pharmacokinetics of MK-8242 in Participants With Advanced Solid Tumors (P07650)Solid TumorsNCT01463696Merck Sharp & Dohme LLC48
招募中
1 期
Study of SC-102 in Patients With Advanced Solid TumorsAdvanced Solid CancersNCT06710158Tianjin ConjuStar Biologics Co., Ltd.120
已完成
1 期
The Tolerability , Pharmacokinetics and Pharmacodynamics Study of HEC96719 Tablets in Healthy Adult SubjectsNonalcoholic Steatohepatitis (NASH)NCT04194242Sunshine Lake Pharma Co., Ltd.64